- Home
- WGRX vs IGC Comparison
WGRX vs IGC Comparison
Compare WGRX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- IGC
- Stock Information
- Founded
- WGRX 2022
- IGC 2005
- Country
- WGRX United States
- IGC United States
- Employees
- WGRX N/A
- IGC N/A
- Industry
- WGRX Other Pharmaceuticals
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- IGC Health Care
- Exchange
- WGRX Nasdaq
- IGC Nasdaq
- Market Cap
- WGRX 43.9M
- IGC 39.8M
- IPO Year
- WGRX 2025
- IGC N/A
- Fundamental
- Price
- WGRX $0.66
- IGC $0.39
- Analyst Decision
- WGRX
- IGC Strong Buy
- Analyst Count
- WGRX 0
- IGC 2
- Target Price
- WGRX N/A
- IGC $4.00
- AVG Volume (30 Days)
- WGRX 41.9M
- IGC 968.4K
- Earning Date
- WGRX 11-19-2025
- IGC 11-14-2025
- Dividend Yield
- WGRX N/A
- IGC N/A
- EPS Growth
- WGRX N/A
- IGC N/A
- EPS
- WGRX N/A
- IGC N/A
- Revenue
- WGRX $36,738,599.00
- IGC $1,327,000.00
- Revenue This Year
- WGRX N/A
- IGC $3.54
- Revenue Next Year
- WGRX N/A
- IGC $15.12
- P/E Ratio
- WGRX N/A
- IGC N/A
- Revenue Growth
- WGRX 82384.51
- IGC 24.95
- 52 Week Low
- WGRX $0.34
- IGC $0.25
- 52 Week High
- WGRX $7.04
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- WGRX 47.00
- IGC 42.43
- Support Level
- WGRX $0.61
- IGC $0.38
- Resistance Level
- WGRX $0.82
- IGC $0.45
- Average True Range (ATR)
- WGRX 0.13
- IGC 0.02
- MACD
- WGRX 0.03
- IGC -0.00
- Stochastic Oscillator
- WGRX 27.76
- IGC 25.28
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.